Results 241 to 250 of about 33,791,512 (292)
Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025. [PDF]
Obesity (Silver Spring)Kildegaard H +4 more
europepmc +1 more source
Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review. [PDF]
BMC Musculoskelet DisordDuru DO +4 more
europepmc +1 more source
WITHDRAWN: Can glucagon like peptide-1 receptor agonists be beneficial for brain health?
Ballabio G +5 more
europepmc +1 more source
How glucagon-like is glucagon-like peptide-1? [PDF]
Diabetologia, 1984 Although glucagon-like peptide-1 has the appearance of a glucagon-homologue that may be co-secreted with glucagon, synthetic glucagon-like peptide-1-(1-37) does not significantly affect plasma glucose and insulin concentrations when administered at high doses (100 and 400 micrograms) to cortisone-pretreated rabbits.
L O Uttenthal, M Ghiglione
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering ...
Tomoya, Mita, Hirotaka, Watada
openaire +2 more sources
Metabolic Messengers: glucagon-like peptide 1
Nature Metabolism, 2021Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents ...
Fiona M. Gribble, Frank Reimann
openaire +2 more sources